Pt. Roberts, WA; Delta, BC – Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca released today’s edition of its series, Investorideas.com potcastsCM – cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good afternoon and welcome to another Investorideas.com potcast; looking at cannabis news, stocks to watch as well as insights from thought leaders and experts. Today’s podcast featrues news announcements from Canopy Growth Corporation (TSX:s WEED and the NYSE: CGC), Namaste Technologies Inc. (TSX-Venture: N ) and Pivot Pharmaceuticals Inc. (CSE: PVOT and OTCQB: PVOTF).
First, we look at Canada’s continued push towards legalization this October.
Today, Health Canada announced the regulations supporting the Cannabis Act. The Cannabis Regulations and the new Industrial Hemp Regulations are based on best practices from the previous regulations for producers of cannabis for medical purposes and industrial hemp as well as extensive consultations held over the past several years.
The regulations include strict specifications for the plain packaging and labelling and analytical testing of all cannabis products as well as stringent physical and personnel security requirements for all federally licensed production sites. They outline details on the licences for cultivation and processing of cannabis, including micro-size licences, industrial hemp, research and analytical testing. The regulations also maintain a distinct system for access to cannabis for medical purposes.
During the transition between Royal Assent and the coming into force of the Cannabis Act on October 17, 2018, the Government of Canada will continue to work with the provinces and territories, Indigenous communities, stakeholders, and regulated parties to promote understanding of, and compliance with, the regulations and help ensure an orderly transition to the new legal framework.
The regulations announced today will be published in the Canada Gazette, Part II, on July 11, 2018, and are available upon request from Health Canada.
Canopy Growth Corporation today released its consolidated financial results for the fourth quarter and fiscal year ended March 31, 2018.
The main highlights from the quarter are:
Total licensed footprint exceeding 2.4 million sq. ft.; 200,000 clones prepared and shipped from Ontario to jump start cultivation in million sq. ft. greenhouses in British Columbia;
Inventory of approximately 15,700 kilograms of dry cannabis, 7,000 liters of cannabis oils and 360 kilograms of softgel capsules at quarter end;
Secured deep channels into Canadian recreational market; multi-year supply agreements, with commitments totaling over 25,000 kg per year, with 5 provinces and territories announced to date; secured private “brick & mortar” and online cannabis retail licenses in Manitoba, Newfoundland & Labrador and Saskatchewan;
Annual and fourth quarter revenue of $77.9 million and $22.8 million, representing year over year increase of 95% and 56%, respectively;
Record Germany quarterly sales of $2.3 million;
Approximately $323 million cash on hand at year-end to fund domestic and global expansion.
“With the recent launch of our Spectrum Softgels, strong sales in Canada and Germany and the expansion of our global footprint into Africa and further into Europe and Australia, we continue to drive our global leadership position in medical cannabis forward,” said Bruce Linton, Chairman & Chief Executive Officer. “The efforts of Canopy Growth and Canopy Health Innovations to develop a range of patented, insurance coverage eligible cannabis-based medicines took a critical step forward with the recent receipt of approval to conduct its first in a planned series of clinical trials. Believing that combining Canopy Health’s growing intellectual property portfolio with our production and advanced manufacturing platform will speed time to market of disruptive medicines, we made the decision to pursue full ownership of Canopy Health Innovations.”
Namaste Technologies Inc. announced the signing of a Master Services Agreement with YPB Group Ltd., an Australian based product verification, and customer engagement company. Namaste has identified the need for its global customers to have confidence in the products they are purchasing, and for vendors to have access to granular data on their end-users. As such, Namaste plans to introduce YPB’s solutions across its network of manufacturers and to Canadian Licensed Producers to bring certainty of authenticity and supply chain transparency to the entire legal cannabis industry globally. This coalition furthers Namaste’s agenda in providing leading technology platforms for its global marketplace and in enhancing the user’s experience for its customers.
Pivot Pharmaceuticals Inc. announce that it will file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and Clinical Trial Application (CTA) with Health Canada to begin human clinical trials of PVT-005, the Company’s pharmaceutical drug candidate for the treatment of Female Hypoactive Sexual Desire Disorder (HSDD).
HSDD, the most common type of female sexual dysfunction (“FSD”), affects approximately 12 million women in the U.S. alone. The condition is characterized by a low sexual desire and marked distress which is not attributable to existing medical, pharmacologic, psychiatric, or relationship issues. Approximately 6 million pre-menopausal women meet the diagnosis for acquired, generalized HSDD.
Using Pivot’s drug formulation and delivery platform technologies, the Company will develop and aim to commercialize a topical cream containing cannabinoids (“PVT-N005”) for perimenopausal, menopausal and post-menopausal women who have noticed a decline in sexual desire and response. While erectile dysfunction in men has been extensively researched, very little has been completed on female sexual dysfunction which can involve reduced sex drive, difficulty becoming aroused, vaginal dryness, lack of orgasm and decreased sexual satisfaction.
Investor ideas remind all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Google Play Music, Stitcher, and Tunein.
Podcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com – News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews, and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Contact InformationD. Van Zant
800 665 0411